| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Loss from operations | -3,672,148 | -3,827,800 | - | |
| Sale of royalty and milestone rights, net | 0 | 0 | - | |
| Interest expense | 213,171 | 268,533 | - | |
| Interest income | 319,147 | 69,848 | - | |
| Other income (expense), net | 3,406 | 10,002 | - | |
| Net income (loss) | -3,562,766 | -4,016,483 | -4,378,307 | |
| Foreign currency translation adjustments | 6,860 | - | 13,090 | |
| Comprehensive income (loss) | -3,555,906 | - | -4,365,217 | |
| Basic (in shares) | 12,755,112 | 8,871,155 | 8,759,053 | |
| Diluted (in shares) | 12,755,112 | 8,871,155 | 8,759,053 | |
| Income (loss) per common share - basic (in usd per share) | -0.28 | -0.45 | -0.5 | |
| Income (loss) per common share - diluted (in usd per share) | -0.28 | -0.45 | -0.5 | |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)